Combination Therapy Using Chugai Pharmaceutical's Chronic Hepatitis-C Agents PEGASYS and Rivabirin Granted Priority Review Status by Government.
PEGASYS is a pegylated interferon agent that treats chronic hepatitis C infection with a once-a-week dosage. The monotherapy using PEGASYS has been covered by the National Health Insurance since December 2003.
With this move, Chugai expects to obtain approval at the earliest date as possible and contribute to the treatment of chronic hepatitis C.
Results of phase III clinical trials for the combination therapy of PEGASYS and rivabirin were presented at the 41st Annual Conference of the Japan Society of Hepatology held in Osaka in June.
Source: JCN http://www.japancorp.net
Copyright [c] 2005 Japan Corporate News Network. All rights reserved.
|Printer friendly Cite/link Email Feedback|
|Publication:||JCNN News Summaries|
|Date:||Sep 16, 2005|
|Previous Article:||Olympus Imaging to Introduce New Entry-level 5-megapixel, 6-megapixel Digital Cameras.|
|Next Article:||Omron Healthcare, Tohoku University Jointly Surveyed 10,000 People on Blood Pressure Measurement.|